<DOC>
	<DOCNO>NCT02521090</DOCNO>
	<brief_summary>This phase I/II trial study side effect best dose epidermal growth factor receptor bispecific antibody ( EGFRBi ) -armed autologous T cell well work treat patient glioblastoma come back respond treatment . EGFRBi-armed autologous T cell coat antibody ( protein use immune system target kill foreign object cancer cell ) may great ability seek , attach , destroy glioblastoma cell .</brief_summary>
	<brief_title>EGFRBi-Armed Autologous T Cells Treating Patients With Recurrent Refractory Glioblastoma</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) 8 intrathecal ( IT ) injection ( via lumbar puncture ) anti-cluster differentiation ( CD ) 3 × anti-EGFRBi arm activated T cell ( aATC ) ( EGFRBi-armed autologous T cell ) give twice per week 4 week standard 3+3 dose escalation schema 0.10 , 0.50 1.00 × 10^9 EGFRBi-aATC per IT injection total 0.8 , 4.0 , 8.0 × 10^9 cell , respectively . ( Phase I ) II . To explore efficacy confirm toxicity profile EGFRBi-aATC . ( Phase II ) SECONDARY OBJECTIVES : I . Measure immune response participant phase I/II trial sequential monitoring phenotype , interferon gamma ( IFN-g ) enzyme-linked immunoSpots ( EliSpots ) , anti-glioblastoma ( GBM ) cytotoxicity peripheral blood mononuclear cell ( PBMC ) ( direct cytotoxicity GBM cell ) direct GBM cell line , T-helper 1 ( Th1 ) /T-helper 2 ( Th2 ) serum cytokine pattern , anti-glioma antibody cerebrospinal fluid ( CSF ) /serum `` vaccinate consolidate '' process . II . Assess survival persistence aATC CSF , traffic IT-injected aATC CSF bloodstream . III . Image patient ' brain magnetic resonance imaging ( MRI ) ( perform clinically 2-month interval ; include standard structural sequence perfusion image ) alpha- [ 11C ] methyl-L-tryptophan ( AMT ) positron emission tomography ( PET ) scan ( Wayne State University [ WSU ] Internal Review Board [ IRB ] /Karmanos Cancer Institute [ KCI ] -approved research protocol ) aATC treatment regimen . OUTLINE : This phase I dose-escalation study follow phase II study . PHASE I : Patients receive EGFRBi-armed autologous T cell IT twice weekly 4 week . PHASE II : Patients receive EGFRBi-armed autologous T cells* IT twice weekly 4 week intravenously ( IV ) 15-30 minute twice weekly 2 week . *NOTE : Six select patient receive EGFRBi-armed autologous T cell IV day -3 , -2 , -1 prior first IT infusion . After completion study treatment , patient follow every 3 month 1 year every 6 month thereafter .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Gliosarcoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<criteria>Histologicallyconfirmed intracranial glioblastoma gliosarcoma ( World Health Organization [ WHO ] grade IV ) evidence clinical radiographic ( compute tomography [ CT ] MRI brain ) tumor progression ( need biopsy proven ) Patients undergone prior resection , radiation therapy , and/or chemotherapy ( except bevacizumab ) Karnofsky performance score &gt; = 70 Eastern Cooperative Oncology Group ( ECOG ) performance status = 0 1 Patient agree undergo baseline followup 11CalphamethylLtryptophan ( AMT ) PET scan immunotherapy ( IMT ) No serious medical psychiatric illness prevents informed consent intensive treatment allow Non pregnant : negative serum test pregnancy , unless male , prior hysterectomy , tubal ligation , postmenopausal ; ( Note : postmenopausal define age &gt; 55 amenorrhea &gt; 1 year age &lt; 55 year amenorrhea 2 year follicle stimulate hormone ( FSH ) level within postmenopausal range institutional parameter ; patient require FSH level determine menopausal status need perform may choose proceed serum pregnancy test ) Required initial laboratory data ( normal limit per treat institution ; minor change indicate laboratory guideline allow discretion treat team special circumstance reason change document ) : Granulocytes &gt; = 1,000/mm^3 Absolute lymphocyte count &gt; = 500/mm^3 Platelet count &gt; = 50,000/ul Hemoglobin &gt; = 8 gm/dl Blood urea nitrogen ( BUN ) = &lt; 1.5 time normal Serum creatinine &lt; 1.8 mg/dl Creatinine clearance &gt; = 50 ml/mm ( calculated utilizing Cockcroft &amp; Gault equation ) Bilirubin &lt; 1.5 time upper limit normal Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 5 time upper limit normal Alkaline phosphatase &lt; 5 time upper limit normal Prothrombin time ( PT ) international normalize ratio ( INR ) activate partial thromboplastin time ( aPTT ) &lt; 1.2 time upper limit normal Negative human immunodeficiency virus ( HIV ) 1/2 serology Negative hepatitis B surface antigen Negative hepatitis C serology Left ventricular ejection fraction ( LVEF ) &gt; = 45 % rest ( multi gate acquisition [ MUGA ] echocardiogram [ ECHO ] ) Each patient must aware nature disease must willingly consent treatment inform alternative , potential benefit , side effect , risk Surgery do prior IMT need palliation , tumor debulking , pathological documentation tumor recurrence ; patient may continue study therapy even measurable disease No investigational agent , immunomodulating agent , cancer chemotherapy permit duration 12 month follow study IMT unless disease progression ; radiotherapy permit ; appropriate antibiotic , blood product , antiemetic , fluid , electrolytes general supportive care use necessary Resective surgery within 2 month prior initial pretreatment AMTPET scan Severe increase intracranial pressure , status epilepticus , serious complication brain tumor , require emergency urgent intervention Patients history another malignancy within 5 year study enrollment Patients extracranial metastasis Evidence active bleeding bleed diathesis Patients ineligible treatment protocol ( prior protocol entry ) : There history recent ( within one year ) myocardial infarction There current prior history angina/coronary symptom require medication and/or evidence depress leave ventricular function ( LVEF &lt; 45 % MUGA ECHO ) There clinical evidence congestive heart failure require medical management ( irrespective MUGA ECHO result )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>